Skip to content

Avanos Medical AVNS Finished goods

Finished goods at other companies

Pacira BioSciences, Inc. logo
Pacira BioSciences, Inc.PCRX
$70.68M+27.2%
Collegium Pharmaceutical, Inc. logo
Collegium Pharmaceutical, Inc.COLL
$21.2M
IAR
Integra LifeSciencesIART
$253.15M+12.3%
Medtronic logo
MedtronicMDT
Baxter International logo
Baxter InternationalBAX
Globus Medical logo
Globus MedicalGMED

Other financials

Income statement

See full
Revenue$182.2M+8.8%
Gross profit$94.2M+4.9%
Operating income$8.9M-13.6%
Net income$5.1M-22.7%
EPS (diluted)$0.11-21.4%

Balance sheet

See full
Cash & equivalents$65.6M-32.4%
Total debt$138.4M-1.8%
Total equity$782.1M-6.8%
Total assets$1.1B-5.2%

Cash flow

See full
Operating cash flow-$12.3M-148%
CapEx$4.3M-35.8%
Free cash flow-$16.6M-187%

Valuation

See full
Market cap$1.17B+108%
Enterprise value$1.24B+105%
P/S1.6×+0.8×

Profitability

See full
Gross margin50%-4.6pp
Operating margin-9.1%-4.2pp
Net margin-10.4%-4.7pp
FCF margin1.6%-14.9pp

Returns & leverage

See full
Return on equity-9.2%-3.9pp
Debt / equity0.2×0.0×
Current ratio2.5×-0.1×

Where this comes from

Reported directly by Avanos Medical in its filing.

Tagged under the XBRL concept us-gaap:InventoryFinishedGoods.

The official record: Avanos Medical’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Avanos Medical's finished goods.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Avanos Medical's finished goods?
Avanos Medical (AVNS) reported finished goods of $78.2M in Q1 2026.
How has Avanos Medical's finished goods changed year-over-year?
Avanos Medical's finished goods increased by 4.5% year-over-year, from $74.8M to $78.2M.
What is the long-term trend for Avanos Medical's finished goods?
Over 5 years (2020 to 2025), Avanos Medical's finished goods has grown at a -1.5% compound annual growth rate (CAGR), from $90.4M to $84M.
What does finished goods mean?
Completed products ready for sale, valued at the lower of cost or net realizable value.